Pharma company recalls four batches of common blood pressure drug over carcinogen concerns
Quinapril is prescribed to around a million Americans each year to treat hypertension and heart failure. However, testing at various sites found excessive amounts of nitrosamine in the pills. (Source: the Mail online | Health)
Source: the Mail online | Health - December 29, 2022 Category: Consumer Health News Source Type: news
Lupin Recalls Quinapril Tablets Due to Potential Carcinogen Lupin Recalls Quinapril Tablets Due to Potential Carcinogen
Lupin ' s voluntary recall of four lots of the antihypertensive quinapril was prompted by unacceptable levels of N-nitroso-quinapril, a likely carcinogen.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 28, 2022 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Drug maker voluntarily recalls blood pressure medication Quinapril
Drug maker Lupin Pharmaceuticals voluntarily pulls blood pressure medication Quinapril over fears of possible elevated cancer risks. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 27, 2022 Category: Consumer Health News Source Type: news
Blood pressure tablets recalled over potential cancer risk, FDA announces
Four lots of the blood pressure medication Quinapril were voluntarily recalled last week by drug manufacturer Lupin Pharmaceuticals Inc. over concerns it could increase the risk of cancer, according to the Food and Drug Administration. Lupin Pharmaceuticals Inc.’s Quinapril tablets, sold in 20 mg…#nnitrosoquinapril #quinapril #chevroletbolt (Source: Reuters: Health)
Source: Reuters: Health - December 27, 2022 Category: Consumer Health News Source Type: news
Blood pressure medicine recalled because of presence of cancer-causing impurity
A Baltimore, Maryland, pharmaceutical company has recalled four lots of a medication for high blood pressure because testing has detected a higher than recommended level of a cancer-causing impurity. Lupin Pharmaceuticals has recalled Quinapril tablets in 20 mg and 40 mg, according to an…#lupinpharmaceuticals #inmarrxsolutionsinc #quinapril #fda #baltimore #ace #inmarrxsolutions #upc #nnitrosoquinapril #maryland (Source: Reuters: Health)
Source: Reuters: Health - December 24, 2022 Category: Consumer Health News Source Type: news
Lupin Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Four Lots of Quinapril Tablets Due to Potential Presence of N-Nitroso-Quinapril Impurity
Lupin Pharmaceuticals Inc. is voluntarily recalling four (4) lots of Quinapril Tablets to the patient (consumer/user) level due to the presence of a nitrosamine impurity, N-Nitroso-Quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level. To date, Lupin has received no rep (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 21, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Aurobindo units recall products in US market for manufacturing issues
The affected lot of the medication, which is used to treat high blood pressure, has been manufactured in India and marketed in the US market by Aurobindo Pharma USA, Inc. As per the USFDA, the company is recalling the affected lot due to "Current good manufacturing practices CGMP deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 8, 2022 Category: Pharmaceuticals Source Type: news
FDA: Here ’s Yet Another Blood Pressure Medication Recall For Cancer Concerns
This time the potential cancer-causing contaminant is Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Quinapril. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 30, 2022 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma Source Type: news
Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Recall of Two (2) Lots of Quinapril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, Due to the Detection of N-Nitroso Quinapril Impurity
East Windsor, New Jersey, Aurobindo Pharma USA, Inc. has initiated a voluntary recall of two (2) lots (refer table below) of Quinapril and Hydrochlorothiazide Tablets USP 20mg / 12.5mg, to the consumer level from the US market due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 25, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Pfizer Recalls More Quinapril Due to Potential Carcinogen Pfizer Recalls More Quinapril Due to Potential Carcinogen
The voluntary recall of five lots of the antihypertensive quinapril (Accupril) was prompted by unacceptable levels of N-nitroso-quinapril, a potential carcinogen.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 27, 2022 Category: Endocrinology Tags: Cardiology News Source Type: news
Accupril Recall; USPSTF Finalizes Aspirin Recs; Cardiologist's COVID Fraud
(MedPage Today) -- Nitrosamines struck again, forcing Pfizer to recall five lots of the antihypertensive medication quinapril HCl (Accupril), according to the FDA.
Consistent with draft recommendations released last fall, the U.S. Preventive Services... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 26, 2022 Category: Cardiology Source Type: news
Pfizer Recalls Another Blood Pressure Medication
Pfizer is recalling five lots of blood pressure medicine Accupril because of elevated levels of a nitrosamine, Nnitroso-quinapril, the company said in a news release posted on the FDA website. (Source: WebMD Health)
Source: WebMD Health - April 25, 2022 Category: Consumer Health News Source Type: news
Pfizer Voluntary Nationwide Recall of Lots of ACCUPRIL ® (Quinapril HCl) Due to N-Nitroso-Quinapril Content
Pfizer is voluntarily recalling five (5) lots of Accupril (Quinapril HCl) tablets distributed by Pfizer to the patient (consumer/user) level due to the presence of a nitrosamine, Nnitroso-quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 23, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Pfizer Voluntary Nationwide Recall of Lots of Accuretic (Quinapril HCl/Hydrochlorothiazide), Quinapril and Hydrochlorothiazide Tablets, and Quinapril HCl/Hydrochlorothiazide Tablets Due to N-Nitroso-Quinapril Content
Pfizer is voluntarily recalling Accuretic (quinapril HCl/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril and hydrochlorothiazide and quinapril HCl/ hydrochlorothiazide) to the patient(consumer/user) level due to the presence (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 5, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
